#United States #Tampa #PainTEQ #SI Joint Fusion #LinQ Technology

PainTEQ Secures Patent for LinQ® Technology

PainTEQ, a prominent player in the field of minimally invasive treatments for sacroiliac (SI) joint dysfunction, has recently been granted a significant patent (US Patent No. 12,121,458) aimed at revolutionizing the SI joint fusion process. This patent represents a critical step forward for PainTEQ's LinQ® SI Joint Stabilization System, enhancing its existing portfolio of single-use instruments.

Advancements in Design and Functionality

The patent introduces two essential mechanisms designed to improve instrument alignment during procedural execution. The first of these innovations involves a joint locator equipped with a keying protrusion that ensures seamless integration with the cannula through a dedicated guidance slot. The second set of claims explores a reversed mechanism where the protrusion is instead located on the cannula, with the joint locator featuring a channel to accommodate it. Together, these methods offer a distinct and effective solution for enhancing procedural precision and ensuring better patient outcomes.

Dr. Sudir Diwan, a respected Pain Management Physician and President of Advanced Spine on Park Avenue, emphasized the advantages of the LinQ system, noting that it surpasses lateral treatment options in effectiveness. He remarked, “LINQ's SI joint fusion is a significant advancement in our treatment of sacroiliac joint dysfunction. Its precision and minimally invasive design deliver superior patient outcomes and dramatically reduce recovery times.” Dr. Diwan has observed firsthand the transformative effects of this innovative approach, which allows patients to regain their mobility and return to daily activities with unprecedented speed and confidence.

Impact on Patient Care

With this new patent, PainTEQ solidifies its intellectual property foundation, enhancing its existing portfolio of alignment tools that are pivotal for successful surgical outcomes. The patented technologies streamline surgical workflows, minimize variability in results, and nurture safety through intuitive, single-use designs tailored for outpatient settings. This commitment to innovation reflects PainTEQ's mission to redefine SI joint dysfunction treatment and underscores its dedication to patient well-being.

Jeremy Carr, Director of Marketing and R&D at PainTEQ, highlighted the company’s ongoing dedication to improving patient care: “By continually innovating and expanding the capabilities of our LinQ® System, we are setting new standards in the industry and enhancing life quality for countless individuals suffering from SI joint pain.”

The LinQ SI Joint Stabilization System is designed as a minimally invasive strategy for alleviating pain associated with sacroiliac joint disease. Through a thorough diagnostic process, healthcare providers can effectively alleviate—often eliminate—chronic pain by inserting a single LinQ allograft into the SI joint.

PainTEQ’s patented instrumentation complements the large graft window of the LinQ system, creating an optimal environment for long-lasting fusion while emphasizing precision and efficiency in procedures. PainTEQ's dedication to innovation is paramount as they strive to enhance the lives of those who live with the debilitating effects of SI joint dysfunction.

Conclusion

As the healthcare landscape continues to evolve, PainTEQ's advancements in the LinQ technology and its recent patent acquisition stand as a testament to the company's pioneering role in the minimally invasive treatment field. By addressing the needs of pain management specialists and their patients, PainTEQ is poised to continue making a positive impact in the realm of pain management and rehabilitation.